Nkarta
A US biotech that seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting.
Latest Nkarta News & Features
11 January 2023
6 December 2022
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze